236 related articles for article (PubMed ID: 26515643)
1. Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients.
Balogh J; Gordon Burroughs S; Boktour M; Patel S; Saharia A; Ochoa RA; McFadden R; Victor DW; Ankoma-Sey V; Galati J; Monsour HP; Fainstein V; Li XC; Grimes KA; Gaber AO; Aloia T; Ghobrial RM
Liver Transpl; 2016 Feb; 22(2):163-70. PubMed ID: 26515643
[TBL] [Abstract][Full Text] [Related]
2. Antifungal prophylaxis in liver transplant recipients: one size does not fit all.
Giannella M; Bartoletti M; Morelli M; Cristini F; Tedeschi S; Campoli C; Tumietto F; Bertuzzo V; Ercolani G; Faenza S; Pinna AD; Lewis RE; Viale P
Transpl Infect Dis; 2016 Aug; 18(4):538-44. PubMed ID: 27237076
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
4. Invasive aspergillosis in liver transplant recipients.
Melenotte C; Aimanianda V; Slavin M; Aguado JM; Armstrong-James D; Chen YC; Husain S; Van Delden C; Saliba F; Lefort A; Botterel F; Lortholary O
Transpl Infect Dis; 2023 Jun; 25(3):e14049. PubMed ID: 36929539
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.
Hellinger WC; Bonatti H; Yao JD; Alvarez S; Brumble LM; Keating MR; Mendez JC; Kramer DJ; Dickson RC; Harnois DM; Spivey JR; Hughes CB; Nguyen JH; Steers JL
Liver Transpl; 2005 Jun; 11(6):656-62. PubMed ID: 15915482
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of invasive fungal infections after liver transplantation and the risk factors of late-onset invasive aspergillosis.
Nagao M; Fujimoto Y; Yamamoto M; Matsumura Y; Kaido T; Takakura S; Uemoto S; Ichiyama S
J Infect Chemother; 2016 Feb; 22(2):84-9. PubMed ID: 26683245
[TBL] [Abstract][Full Text] [Related]
7. Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey.
He SY; Makhzoumi ZH; Singer JP; Chin-Hong PV; Arron ST
Transpl Infect Dis; 2015 Feb; 17(1):14-20. PubMed ID: 25620387
[TBL] [Abstract][Full Text] [Related]
8. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
11. Preexisting Cerebral Aspergillosis Successfully Treated After Liver Transplantation: A Case Report.
Lee JS; Kim SH; Kwon JH; Yoon YC
Transplant Proc; 2017 Dec; 49(10):2402-2405. PubMed ID: 29198690
[TBL] [Abstract][Full Text] [Related]
12. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients.
Tofte N; Jensen C; Tvede M; Andersen CB; Carlsen J; Iversen M
Scand J Infect Dis; 2012 Nov; 44(11):835-41. PubMed ID: 22803836
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
[TBL] [Abstract][Full Text] [Related]
14. Aspergillus pseudodeflectus: a new human pathogen in liver transplant patients.
Aït-Ammar N; Levesque E; Murat JB; Imbert S; Foulet F; Dannaoui E; Botterel F
BMC Infect Dis; 2018 Dec; 18(1):648. PubMed ID: 30541477
[TBL] [Abstract][Full Text] [Related]
15. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].
Mattner F; Chaberny IF; Weissbrodt H; Fischer S; Gastmeier P; Haubitz B; Gottlieb J; Mattner L; Strueber M
Mycoses; 2005; 48 Suppl 1():51-5. PubMed ID: 15826288
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
17. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
18. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
Herbrecht R; Patterson TF; Slavin MA; Marchetti O; Maertens J; Johnson EM; Schlamm HT; Donnelly JP; Pappas PG
Clin Infect Dis; 2015 Mar; 60(5):713-20. PubMed ID: 25414266
[TBL] [Abstract][Full Text] [Related]
19. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
[TBL] [Abstract][Full Text] [Related]
20. Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases.
Barchiesi F; Mazzocato S; Mazzanti S; Gesuita R; Skrami E; Fiorentini A; Singh N
Liver Transpl; 2015 Feb; 21(2):204-12. PubMed ID: 25348192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
